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of ANGPTL8/BetatrophinFigure 1. Hydrodynamic Tail Vein Injection of Mouse ANGPTL8/Betatrophin Plasmid DNA
Induces Pancreatic Beta Cell Proliferation with Significant Variability, and hBetatrophin
Exists in a Large Protein Complex in Serum
(A) Pancreatic beta cell proliferation rate (% Ki67+/insulin+) after hydrodynamic tail vein injection of GFP
(n = 14mice) ormBetatrophin (n = 38mice) plasmids (p = 0.016). This figure combines data from 5 separate
experiments.
(B) The data from our original report (Yi et al., 2013, Figure S3F) is replotted in the same format.
(C) Human serum fractionated in a nondenaturing gel stained with anti-hBetatrophin antibody.
hBetatrophin migrates as a high molecular weight (480–1,000 kDa) complex compared to recombinant
hBetatrophin protein (60–100 kDa. Phoenix Pharmaceuticals).In this issue of Cell, Gusarova et al. (2014)
show that deletion of ANGPTL8 in mice
does not affect the compensatory prolif-
eration of pancreatic beta cells in
response to insulin resistance induced
by a high-fat diet or treatment with the in-
sulin antagonist S961. They also show
that overexpression of human ANGPTL8
in mouse liver leads to elevated serum
triglyceride levels but not significant
pancreatic beta cell proliferation. They
conclude that ANGPTL8 (also called beta-
trophin [Yi et al., 2013]/RIFL [Ren et al.,
2012]/lipasin [Zhang, 2012]) does not con-
trol pancreatic beta cell expansion. Their
experimental design and data are clearly
presented and straightforward, and we
agree with their conclusions. Our own
follow-up experiments using an indepen-
dent knockout of ANGPTL8 produced
the same result. Taken together, these
new data contradict our previous conclu-
sion (Yi et al., 2013) that betatrophin is the
sole agent responsible for beta cell prolif-
eration following S961 treatment. Further-
more, these new results cast doubt on the
finding that beta cell proliferation can be
induced by overexpression of ANGPTL8/
betatrophin.
The work presented in Yi et al. (2013)
hadat its foundation the finding that the in-
sulin antagonist S961 causes a specific
and robust increase in beta cell prolifera-
tion and subsequently beta cell mass.
This finding has now been reproduced
by Kaestner’s group (Jiao et al., 2014)
and Gusarova et al. However, additional
experiments by our lab (Figure 1A) and
those by Gusarova et al. (Gusarova et al.,
2014; Figures 2F and S1) using tail
vein injection to overexpress ANGPTL8/
betatrophin show a significant and unsat-
isfactory variation, perhaps as a result
of liver inflammation, which makes it diffi-
cult to draw a secure conclusion about
beta cell replication. InYi et al.we reported
an average beta cell replication rate of
4% in betatrophin-injected mice (n = 7);
with five additional experiments (n = 52
mice in total), the averagebeta cell replica-
tion rate in betatrophin-injected mice
drops to 1.2%. While still significantlyabove control levels (p = 0.016 for all ex-
periments) of beta cell replication (0.6%),
the conclusion from Yi et al. must be cor-
rected and modified with respect to the
magnitude of the effect. A confounding
issue is that these injection experiments
show a ‘‘jackpot’’ effect on beta cell repli-
cation (Figures 1A and 1B); some mice
respond strongly to ANGPTL8/betatro-
phin expression but many do not. When
all mice are taken into account (three ex-
periments in Yi et al. [Yi et al., 2013], five
new experiments here in Figure 1A, and
Gusarova et al. [Gusarova et al. 2014]),
and compared to control injected animals,
the results show a modest average in-
crease in beta cell replication.Cell 159In all, the variation in beta cell replica-
tion following tail vein injection with DNA
should either be ignored because it is an
artifact or further pursued as a clue to
the numerous and complex functions of
the ANGPTL gene family. With respect
to the latter, one possibility is that
ANGPTL8 requires a binding partner that
can be induced by tail vein injection. Of in-
terest in this regard is ANGPTL3, which is
structurally similar to ANGPTL8 and is
located in the intron of a Dock gene as is
ANGPTL8. Moreover, deletion or overex-
pression of ANGPTL3 and ANGPTL8
have similar effects on serum triglycerides
(Quagliarini et al., 2012; Santulli, 2014).
Hobbs and colleagues have previously
shown that these Angptl proteins exist in
large complexes and demonstrated that
these proteins regulate serum triglycer-
ides (Quagliarini et al., 2012). We find
similar results with respect to the large
protein complexes (Figure 1C) consistent, October 23, 2014 ª2014 Elsevier Inc. 467
with the notion that the members of this
family do not act alone. Together these
data suggest to us that further analysis
of whether and how members of the
Angptl family interact, perhaps having
redundant functions, is warranted.
Another approach to investigating this
issue is to find the receptor for Angptl8/
betatrophin or its protein complex and
study the function of the receptor on
beta cell proliferation. We have cloned
two membrane proteins that bind to
Angptl8/betatrophin. One, Marco, is ex-
pressed in macrophages found in the
pancreas and known to regulate lipid
metabolism (Perez et al., 2010). The other
receptor is RTN4R, a neuronal receptor
(Fournier et al., 2001). It is possible that
Angptl8/betatrophin uses the macro-
phage receptor to regulate lipid/triglycer-
ide metabolism and the neuronal receptor
actually mediates the signaling to pancre-
atic beta cells through nerves. To date, no
direct connection has been established
between changes in triglycerides and
beta cell replication induced by S961
treatment. It is interesting that neuronal
signal has been shown to promote beta
cell proliferation in insulin resistance sta-
tus (Imai et al., 2008), and the magnitude
of the beta cell proliferation Imai et al.
observed is very similar to some of our
Angptl8/betatrophin hepatic overex-
pressed mice.
In summary, Gusarova et al. confirmed
our original finding that the insulin recep-468 Cell 159, October 23, 2014 ª2014 Elsevitor antagonist S961 causes dramatic
pancreatic beta cell replication, thus
providing an important research tool for
studying beta cell proliferation. And we
agree with the main conclusion of Gu-
sarova et al., namely that deletion of
Angptl8/betatrophin itself does not sup-
port the idea that betatrophin alone is a
capable of inducing pancreatic beta
cell proliferation. The mechanisms con-
trolling beta cell replication are clearly
more complicated than we put forth in
Yi et al. (Yi et al., 2013). The new data
provided by Gusarova et al. helps clarify
the emerging understanding of how
members of the Angptl family effect
serum triglycerides and weakens the
case that there is a direct link to beta
cell replication. The agents responsible
for inducing beta cell replication
following S961 treatment may be triglyc-
eride levels, members of the Angptl fam-
ily, or some other factor(s) yet to be
identified. We are committed to solving
this puzzle in mice and then move on
to determine whether or not any of these
findings in mice are relevant to the hu-
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